Canaccord Genuity Group cuts Akoya Biosciences' price target to $6.00, and Capital One Financial lowers Q2 2024 EPS estimates to ($0.28).
Akoya Biosciences (NASDAQ:AKYA) had its price target cut to $6.00 by Canaccord Genuity Group and Capital One Financial lowered their Q2 2024 EPS estimates to ($0.28) per share, down from ($0.26). Akoya last reported a Q1 EPS of ($0.22), beating expectations of ($0.27). The consensus estimate for the company's full-year earnings is ($0.87) per share.
May 18, 2024
3 Articles